{"name":"Attralus, Inc.","slug":"attralus-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AT-02","genericName":"AT-02","slug":"at-02","indication":"Other","status":"phase_1"},{"name":"124I-AT03","genericName":"124I-AT03","slug":"124i-at03","indication":"Other","status":"phase_1"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"124I-AT-01","genericName":"124I-AT-01","slug":"124i-at-01","indication":"Lysosomal acid lipase deficiency","status":"phase_2"}]}],"pipeline":[{"name":"124I-AT-01","genericName":"124I-AT-01","slug":"124i-at-01","phase":"phase_2","mechanism":"124I-AT-01 is a small molecule targeting the lysosomal acid lipase (LAL) enzyme.","indications":["Lysosomal acid lipase deficiency"],"catalyst":""},{"name":"AT-02","genericName":"AT-02","slug":"at-02","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"124I-AT03","genericName":"124I-AT03","slug":"124i-at03","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPRGZ4UTZBV2tRTW5iUVJzNGl5LV9pWW9JeEVHUmJBM2pFZVpNTmx3ZWF1cjNhR1Q5b1JhR3BZNEpkSEwxaHBsZU5Mc1Q3TWlBZGpsWTFWRXYzQlV6V0lVd0NUdzVjY05va1ZOQXN6VXNGVEUtRHN6Y0xYQllyMUtNd3hfQ1JCMGZCMzFLdk1xNnBETVl2Zk04?oc=5","date":"2026-04-07","type":"pipeline","source":"openPR.com","summary":"Amyloidosis Therapeutics Market to Reach USD 6.3 Billion by 2035, Driven by Targeted Treatment Innovations - openPR.com","headline":"Amyloidosis Therapeutics Market to Reach USD 6.3 Billion by 2035, Driven by Targeted Treatment Innovations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQX1JWcm5nQkVZUzUxal84Vkg2NWNTVzJaRGNwR21OamxndERQWUNRSWxwYVhOVmxaMmtQS1hnRjNiVUNXM3pYVDJHaFEyUTFlbjZELWx2eldkSnBtQl9wemRxS3NsQno2MkRiNmc1T29hT0RpYWcwNkhESXlCT0Y5emgxN3JiYzZBWW1PY1N5LVcxS0VKVjJKaWFCUnFkWDR4T1lNU0J3akl6WG9yT1k2RmtiTQ?oc=5","date":"2026-01-13","type":"deal","source":"Contract Pharma","summary":"Bayer Acquires Attralus Radiotracers, Expands into Molecular Imaging - Contract Pharma","headline":"Bayer Acquires Attralus Radiotracers, Expands into Molecular Imaging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNczhnY0l1UEJvYm43VU9paWZhT3hLaUtlRl9vaUQ5NzBQdkZFUDZmelV3dlhPencycUV6WGJFeUJXY2FWOFViVUllWXJwNnI4WE9BX096b21BSk00ekVoUjgzYzdrbHA5Z2Vfbm1jUmZ2b3FhVExEYUJXOGlDYWVvTzBOa0ZreWp3TGtfeVNHVmM1TmhpcDMzaVJsQnFuNHlGVnBtYXZWTEdEcW9lcW5KYmgxTXdHMnFZVFVweFZyV25SYnNVanpJako0SndUOHlJM0ZNOEpYNFNodw?oc=5","date":"2026-01-13","type":"pipeline","source":"Cardiovascular Business","summary":"Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions - Cardiovascular Business","headline":"Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPZ20wU2ExdnU0cUpxZnlTY0xOR3gwck0zYmhsaVpneTBMeS1nbkU1bE5RbG1Ha3FISmNyTXBtQ1hhRXJpME9OTEIxMmhQOTNGbUxQTlFzY3hINnhTZGhhcWM3V2U0cDFyeWxKRjdNTmlXcEQtTmdBRTZBeVhlM3FVbnlubERSaURnMmhSbWlQcEgyeFlYa21CbWNDX2JKOUtITXdaSTNuYWxRLTZFOE5ESWRGbFZuMjA?oc=5","date":"2026-01-13","type":"pipeline","source":"Radiology Business","summary":"Bayer expands into molecular imaging with 2 acquisitions - Radiology Business","headline":"Bayer expands into molecular imaging with 2 acquisitions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQVDM1Y3paRWJIRkY2bnIza2Rmdzl1QnJHYl90M3JmcS1lOXd1TUhmeW9oNF9xS2lJeDdBTnUxZzhXNG94MVN1aXZIbzFQYWFJeVZELW1tVFpLT3VUUGVBT1JRSk44Z2wxWGdPTmxYNi14YmMyQ3ZUOExUMWViaFZKN0ZPX1RRRGJkRDlQSWFsSTRraFIybkhyVmNvMkxySVl0aERSUzFB?oc=5","date":"2026-01-12","type":"deal","source":"Fierce Biotech","summary":"Bayer boosts imaging portfolio with Attralus deal for 2 diagnostic tracers - Fierce Biotech","headline":"Bayer boosts imaging portfolio with Attralus deal for 2 diagnostic tracers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNUFZWSlhISjRHLU1YeVY1b0JFbFBOWDhfNzFxYlFBQ0hxX0w3LWhSOXh5WmFTdkNIZlJEQ0VaWEJUZG8yMVZRaENnSmFRZGhCOHBfVW9WSHdWMzBQT0tjM0xxeTV5U1FyWl90d1BvWWU3a2EzN3B0Y29LeXRFaDlRTWtwdDBBanZ0NzZyVl9nZmpkSnk4WUFsckZ1eGtfdWdlOHRqejE5c0hDb0ZIdlpIN1lrTDF2SzQxSWx4V1ZadC15U01ib3NiRHp6YndNVWpjektBaGNVenlILUFzMmRVZHhvT29qblNmY19UVFNhNU1JMWZaN1ZoTnhkakE5RWhST19ENkVQNkVFSE5rTTM0N3FQMDI?oc=5","date":"2024-11-12","type":"pipeline","source":"globenewswire.com","summary":"Attralus Therapeutic AT-02 Receives Orphan Drug Designation - globenewswire.com","headline":"Attralus Therapeutic AT-02 Receives Orphan Drug Designation","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-24","type":"regulatory","source":"PR Newswire","summary":"Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Players - Attralus, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Alexion","headline":"Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Players ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQbHg2X0gwLWNEQVA1YjJTazQwdEUweEdRalV1SEVFdFJpUE03dUMyMmVuWXB0ZlJWZDEyY2s2cVlPR1NUUXBUamJsajJrYzVEckU2RGhuVmFHa2ltVlEwR0lWSzhUNVp1U3hHWmJKaDV6aVUwLWpiZ3dYTlEzTlRGelg1MDJERUE2d1Br?oc=5","date":"2022-03-18","type":"pipeline","source":"Pharma Voice","summary":"Attralus’ medical officer believes systemic amyloidosis could be ‘solvable’ - Pharma Voice","headline":"Attralus’ medical officer believes systemic amyloidosis could be ‘solvable’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPQVF1N2txeWVqb3JtSTJkdHdVdjg3dVhFTkJvOWpVVER3a2pKOHh2U2czUUlWMWtRU3lIdUJqV1FGS1ROc0JodTZEVnFORk92bVlvVTZQQUplRDN0bWQxNFpZU3pzQ3RoNmFuZWxnN1RQVjRiSC1CM2FfbFNQV01HeGt4dUJRNVA4RTI5ajI5WGRqZ3VqTGlnaUxiNlY2UTdSbTVHVDU3VmNOcll5Q0tzb0lUdVBIR2xUVC03Yg?oc=5","date":"2021-09-08","type":"pipeline","source":"Fierce Biotech","summary":"Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent - Fierce Biotech","headline":"Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNMXVwdzloeDJLQTdhSzFsVF9kZDVnbW9FZWY3Q0JRLUszeEl6aFBwT2J2MGZqTGJkdTlrSWljR0VGQlVGQXVoT3R5bE5YZWJFYV9GcHRVS1h5RFFOMWJaZXlORi1FTHFWT1lpa2d1RjdwcXA3UmQyYnRZVE9UajFCamJqUHpndDkxTm02dm4zcGRNdjZLc3MyXzc2WEU?oc=5","date":"2021-05-11","type":"pipeline","source":"Fierce Biotech","summary":"Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus - Fierce Biotech","headline":"Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQY21zVW43dXhJLXdYbnFFSktmRUxNcmhBUmJad0lnVEU4MWpvaFNGZTllXzg4TlRCdlM1VkxSb0VjY0Q4QmJ2UVNoa2RneUlZdHd4R2JUeExvS0VEc3R0SzJodVRRZHpNMmlkaW43YlVteTIyT1U5SVk4VGV4TThmcWZhQ3JQY1NnRnpaeXR3?oc=5","date":"2020-10-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A - Pharmaceutical Technology","headline":"Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}